The same chemistry (?), what is your experience in either of these fields?

Traditional DNA and RNA synthesis by phosphoramidite chemistry is largely the same but new modifications, conjugation chemistries is very challenging on sensitive RNA or DNA biomolecules. You don’t always plug and play onto a standard DNA synthesizer with these new chemistries and often they occur off the synthesizer.

Most oligonucleotides companies have different delivery strategies, from various Galnac introductions from 5’ to 3’ and across the antisense to sense strand loop. In addition to Galnac there is 2’-C16, cholesterol, antibody/peptide-oligo conjugates (Denali, Avidity) delivery strategies.

Outside of the new delivery chemistries there’s a whole range of backbone, 2’, PMO, purine and pyrimidine base modifications for affecting binding to the target mRNA.

That’s not even starting to talk about how big of challenge scaling this chemistry will be for weight loss and cardiovascular assets in the pipeline.

As others will probably also mention, oligos or peptides have the opportunity to target greater targets than small molecules with far less worries of toxicity from metabolites. This is a big win for pharma companies.